Designed to assess the safety, tolerability and pharmacokinetic profile of twice daily V81444 for 14 days, the study is being conducted in 24 subjects with a confirmed diagnosis of one of the potential indication.
The randomised, double-blind study is being conducted at a single US site under an approved Investigational application.
Placebo controlled study will also provide initial proof of concept for use of V81444 as a potential treatment for the CNS indication.